Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER

Merck lifts full-year forecast as Keytruda sales soar

Stock Markets Oct 27, 2022 12:51PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid
 
LLY
-1.70%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
WFC
+0.68%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PFE
-1.04%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Michael Erman and Leroy Leo

(Reuters) -Merck & Co on Thursday reported higher-than-expected third-quarter sales and profit on a jump in demand for blockbuster cancer immunotherapy Keytruda and human papillomavirus vaccine Gardasil.

Merck shares were up about 2% in midday trading as the U.S. drugmaker also raised its full-year sales and profit forecast despite the impact of a weak euro and pound. The company's shares are up over 30% year-to-date, well outperforming the broader market.

Merck has been looking to pursue deals to protect itself from an eventual revenue loss as Keytruda patents begin to expire toward the end of the decade. The company was reportedly in talks to buy cancer focused biotech Seagen Inc over the summer, but a deal did not materialize.

"Our urgency on business development has not changed. We do see a list of potential places to play," Merck Chief Executive Robert Davis said on a conference call with analysts. "Obviously, we've got to bring them through to fruition, which we're working to do."

Chief Financial Officer Caroline Litchfield said that one difficulty in reaching deals is agreeing on valuation.

"We continue to see sellers' expectations lag what the marketplace looks like," she said in an interview.

Merck announced on Wednesday that Davis would take on the additional role of chairman as of Dec. 1, succeeding incumbent and former CEO Ken Frazier.

Keytruda sales jumped 20% to $5.4 billion for the quarter, in line with analysts' estimates. Gardasil sales rose 15% to $2.3 billion, topping expectations by more than $200 million.

Gardasil's performance "reflects growing international demand and potentially a normalization from COVID trends in the U.S.," Wells Fargo (NYSE:WFC) analyst Mohit Bansal said in a note.

The company also posted slightly better-than-expected sales of its COVID-19 antiviral drug Lagevrio (molnupiravir), which it developed and shares with Ridgeback Biotherapeutics.

Merck benefited from its foreign exchange hedging program, which added roughly $300 million to quarterly revenue, partially offsetting pressure on overseas sales, CFO Litchfield said.

"Foreign exchange will continue to be a headwind," she said, adding that the impact of Merck's hedging program is likely to be more subtle in 2023 as the pace of the dollar's strengthening slows.

Sales by Merck's animal health business missed analysts' estimates. BMO Capital Markets analyst Evan Seigerman called that "the only point of concern," but noted the unit had enjoyed significant growth earlier in the pandemic.

Some investors have suggested Merck follow rivals Eli Lilly (NYSE:LLY) and Co and Pfizer Inc (NYSE:PFE) by spinning off its animal health business. Davis said the company has no plans to do so.

"We're benefiting from what it brings to us and we continue to see it as a strategic asset," the CEO said.

Merck now expects to earn $7.32 to $7.37 per share for 2022, up from its prior view of $7.25 to $7.35. It beat analysts' estimates for adjusted profit in the quarter by 14 cents.

Merck lifts full-year forecast as Keytruda sales soar
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Ac Tektrader
Ac Tektrader Oct 27, 2022 3:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
more spam from szechuan....
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email